Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant and Adjuvant Olaparib Plus Pembrolizumab Following Platinum Based Chemotherapy Plus Pembrolizumab for Germline BRCA Mutated Triple Negative Breast Cancer (WJOG14020B/OPERETTA)

NCT05485766 is registered in ClinicalTrials.gov with Okayama University as lead sponsor.

NCT NCT05485766
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05485766 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant and Adjuvant Olaparib Plus Pembrolizumab Following Platinum Based Chemotherapy Plus Pembrolizumab for Germline BRCA Mutated Triple Negative Breast Cancer (WJOG14020B/OPERETTA)
Lead sponsor
Okayama University
Phase
Phase 2
Overall status
Recruiting
Start date
July 16, 2024
Completion date
September 30, 2028
Enrollment
23 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

brca mutation, brca-associated breast carcinoma, brca1 mutation, brca2 mutation, breast cancer, breast neoplasms, triple negative breast cancer, triple negative breast neoplasms